Toggle Nav
Close
  • Menu
  • Setting

Anti-DLL4 Antibody (Navicixizumab)

Catalog No.
F1540
Anti-DLL4 Antibody (Navicixizumab)
Grouped product items
SizePriceStock Qty
100ug
Please inquire
Ship with 3-5 days
1mg
Please inquire
Ship with 3-5 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can be used in combination with paclitaxel for cancer research. Navicixizumab can be used in the study of ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Quality Control

Quality Control & DataSheet

View current batch:
 

M.Wt

146.17 kDa

Shipping

Dry ice

Cas No.

1638338-43-8

Storage

-80°C

Expiration Date

2 years

Form

Liquid

Concentration

See label

Reconstitution

For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.

Host

CHO

Alternative Names

OMP-305B83

Buffer System

100 mM Pro 20 mM Arg pH 5.0. No preservative!

Target Accession

Q9NR61

Reactivity

Human

Conjugation

Unconjugated

Clonality

Monoclonal

Purification

Protein A

Isotype

IgG2SA

Application

ELISA, FACS, Kinetics, Functional assay, Animal Model

Biological Activity

Immobilized human VEGF165 His at 2 ug/mL can bind Anti-DLL4 Antibody (Navicixizumab)

Target

DLL4

Note

Please avoid freeze-thaw cycles.